Viking Therapeutics, Inc.
LSE: 0VQA.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Brian Lian
- Employees
- 45
- Headquarters
- San Diego, United States
- IPO year
- 2018
- Market cap
- $3.7B
- Website
- https://www.vikingtherapeutics.com
Loading 0VQA…
Loading profile data…Frequently asked questions about 0VQA
What does Viking Therapeutics, Inc. (0VQA.L) do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
Where does 0VQA.L trade?
Viking Therapeutics, Inc. (0VQA.L) trades on the London Stock Exchange.
What sector is 0VQA.L in?
Viking Therapeutics, Inc. (0VQA.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Viking Therapeutics, Inc.?
Brian Lian is the chief executive officer of Viking Therapeutics, Inc. (0VQA.L).
Where is Viking Therapeutics, Inc. headquartered?
Viking Therapeutics, Inc. is headquartered in United States.
Does 0VQA.L pay a dividend?
Viking Therapeutics, Inc. (0VQA.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0VQA.L go public?
Viking Therapeutics, Inc. (0VQA.L) completed its initial public offering in 2018.